[go: up one dir, main page]

PL1865976T3 - Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca - Google Patents

Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca

Info

Publication number
PL1865976T3
PL1865976T3 PL06749753T PL06749753T PL1865976T3 PL 1865976 T3 PL1865976 T3 PL 1865976T3 PL 06749753 T PL06749753 T PL 06749753T PL 06749753 T PL06749753 T PL 06749753T PL 1865976 T3 PL1865976 T3 PL 1865976T3
Authority
PL
Poland
Prior art keywords
heart failure
natriuretic peptide
treating heart
treating
natriuretic
Prior art date
Application number
PL06749753T
Other languages
English (en)
Inventor
Veselin Mitrovic
Hartmut Luss
Wolf-Georg Forssmann
Markus Meyer
Klaus Dohler
Original Assignee
Cardiorentis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiorentis Ag filed Critical Cardiorentis Ag
Publication of PL1865976T3 publication Critical patent/PL1865976T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL06749753T 2005-04-07 2006-04-07 Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca PL1865976T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66978605P 2005-04-07 2005-04-07
US66975105P 2005-04-08 2005-04-08
US73258505P 2005-11-01 2005-11-01
EP06749753A EP1865976B1 (en) 2005-04-07 2006-04-07 Use of natriuretic peptide for treating heart failure
PCT/US2006/013471 WO2006110743A1 (en) 2005-04-07 2006-04-07 Use of natriuretic peptide for treating heart failure

Publications (1)

Publication Number Publication Date
PL1865976T3 true PL1865976T3 (pl) 2012-11-30

Family

ID=37087353

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12156696T PL2510942T3 (pl) 2005-04-07 2006-04-07 Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
PL06749753T PL1865976T3 (pl) 2005-04-07 2006-04-07 Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12156696T PL2510942T3 (pl) 2005-04-07 2006-04-07 Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca

Country Status (10)

Country Link
US (5) US7732406B2 (pl)
EP (2) EP2510942B1 (pl)
CY (1) CY1113183T1 (pl)
DK (2) DK2510942T3 (pl)
ES (2) ES2392892T3 (pl)
HU (1) HUE026231T2 (pl)
PL (2) PL2510942T3 (pl)
PT (2) PT2510942E (pl)
SI (1) SI2510942T1 (pl)
WO (1) WO2006110743A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
WO2006110743A1 (en) 2005-04-07 2006-10-19 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
US7606617B2 (en) * 2006-01-31 2009-10-20 Cardiac Pacemakers, Inc. Urinalysis for the early detection of and recovery from worsening heart failure
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
PT2765139T (pt) 2007-07-20 2017-07-14 Mayo Foundation Polipéptidos natriuréticos
EP2078530A1 (en) * 2008-01-08 2009-07-15 Pharis Biotec GmbH Use of natriuretic peptides for treating angioedema syndromes
US8293711B2 (en) 2007-09-11 2012-10-23 Pharis Biotech Gmbh Use of natriuretic peptides for treating angioedema syndromes
MX2011003117A (es) 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
US20130197188A1 (en) * 2010-03-15 2013-08-01 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
WO2012115772A2 (en) * 2011-02-25 2012-08-30 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US20150038418A1 (en) * 2011-07-27 2015-02-05 Medtronic, Inc. Natriuretic peptide compositions and methods of preparation
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014115033A2 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
CN109838289B (zh) * 2017-11-27 2022-03-15 罗伯特·博世有限公司 尿素水溶液喷射系统的回抽过程监测系统和方法
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
US12433938B2 (en) 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2021183928A1 (en) * 2020-03-13 2021-09-16 Mayo Foundation For Medical Education And Research Assessing and treating acute decompensated heart failure
WO2022029499A1 (en) * 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Methods of treating refractory ascites
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346953A1 (de) * 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US5449751A (en) * 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
DE3878231T2 (de) 1987-03-02 1993-05-27 Bissendorf Peptide Gmbh Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
US5461142A (en) * 1987-11-07 1995-10-24 Pharma Bissendorf Peptide Gmbh Phosphorylated derivatives of cardiodilatin/ANF peptides
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
ES2188665T3 (es) * 1994-06-02 2003-07-01 Forssmann Wolf Georg Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
WO1998045329A1 (en) 1997-04-04 1998-10-15 Novo Nordisk A/S Natriuretic peptide derivatives
DE19951471A1 (de) * 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
US6831084B1 (en) 1999-11-12 2004-12-14 Wyeth Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
NZ525389A (en) 2000-10-04 2009-04-30 Molecular Medicine Res Inst Methods of modulating apoptosis by administration of relaxin agonists or antagonists
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
WO2003081246A1 (en) 2002-03-18 2003-10-02 Scios Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
DE60331584D1 (de) * 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
CA2597460A1 (en) 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
WO2006110743A1 (en) * 2005-04-07 2006-10-19 Cardiopep Pharma Gmbh Use of natriuretic peptide for treating heart failure
WO2008073448A2 (en) 2006-12-12 2008-06-19 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations and methods for making the same
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
KR20100057641A (ko) 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 인터메딘 ４７ 및 ５３ 펩티드의 치료적 용도
US8293711B2 (en) 2007-09-11 2012-10-23 Pharis Biotech Gmbh Use of natriuretic peptides for treating angioedema syndromes
WO2009086166A1 (en) 2007-12-19 2009-07-09 Ekr Therapeutics, Inc. Room temperature stable, lyophilized natriuretic peptide formulations
WO2009086126A2 (en) 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2010048308A2 (en) 2008-10-24 2010-04-29 Deborah Dickey Natriuretic polypeptides
CA2745288A1 (en) 2008-12-03 2010-06-10 Alisa Kabcenell Antibodies for guanylyl cyclase receptors
EP2413969A4 (en) 2009-03-30 2012-09-05 Boehringer Ingelheim Int FUSION PROTEINS WITH DOG FC ELEMENTS
US20110065676A1 (en) 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists
US20110014180A1 (en) 2009-07-16 2011-01-20 Masafumi Koide Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue
US8551938B2 (en) 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
UY32902A (es) 2009-09-25 2011-02-28 Alcon Res Ltd Nuevos agonistas de npr-b
US20130197188A1 (en) 2010-03-15 2013-08-01 Wolf-Georg Forssmann Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
US20120052097A1 (en) 2010-08-20 2012-03-01 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods

Also Published As

Publication number Publication date
US7732406B2 (en) 2010-06-08
ES2392892T3 (es) 2012-12-14
PT2510942E (pt) 2015-12-28
US20150224174A1 (en) 2015-08-13
CY1113183T1 (el) 2016-04-13
PL2510942T3 (pl) 2016-02-29
EP2510942A1 (en) 2012-10-17
US8710006B2 (en) 2014-04-29
SI2510942T1 (sl) 2016-01-29
US20110257099A1 (en) 2011-10-20
DK1865976T3 (da) 2012-07-23
EP1865976A1 (en) 2007-12-19
WO2006110743A1 (en) 2006-10-19
US20060264376A1 (en) 2006-11-23
EP1865976A4 (en) 2010-09-01
US9358271B2 (en) 2016-06-07
PT1865976E (pt) 2012-08-03
US20160324931A1 (en) 2016-11-10
US20140287999A1 (en) 2014-09-25
ES2554713T3 (es) 2015-12-22
DK2510942T3 (en) 2015-12-14
EP1865976B1 (en) 2012-05-23
EP2510942B1 (en) 2015-09-02
HUE026231T2 (en) 2016-06-28
US9023794B2 (en) 2015-05-05

Similar Documents

Publication Publication Date Title
PL1865976T3 (pl) Zastosowanie peptydu natriuretycznego do leczenia niewydolności serca
GB2440809B (en) Improved heart valve prosthesis
IL248964A0 (en) Arterial supports for the treatment of arterial blockages in the body
IL187703A0 (en) Treatment of protein folding disorders
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
IL189420A0 (en) Method for the recombinant expression of a polypeptid
TWI340645B (en) Solution for tissue adhesion prevention
GB2429013C (en) Peptides for treatment and diagnosis of autoimmunedisease
PL1685834T3 (pl) Zastosowanie kwasu pinolenowego do leczenia otyłości
EP1729687A4 (en) HEART VALVE
EP2091480A4 (en) SYSTEM FOR THE TREATMENT OF HEART TISSUE
EP1946724A4 (en) PROSTHESIS OF HEART VALVE
EP1923078A4 (en) TISSUE REGENERATION SUBSTRATE
PT1945243E (pt) Utilização da calcitonina para o tratamento da ar
EP1871462A4 (en) DC TISSUE TREATMENT
GB0505975D0 (en) Novel use of peptide
GB0525540D0 (en) New treatment
SI1865976T1 (sl) Uporaba natriuretskega peptida za zdravljenje srčne odpovedi
GB0609121D0 (en) Peptide Therapy
EP1859803A4 (en) MEANS OF PROMOTING THE FORMATION OF HARD FABRIC
GB0618060D0 (en) Treatment of polyamides
EP2166020A4 (en) PEPTIDE HAVING HYPOTENSIVE ACTIVITY
IL186812A0 (en) Dc tissue treatment
GB0515776D0 (en) Insulin stimulating peptide
GB0518003D0 (en) Treatment of hepatatis c